MedWatch

Lundbeck has come this far with Alzheimer’s vaccine

Lundbeck has seen notable advances for its vaccine candidate against Alzheimer’s, Vaccinil, as of late. For some time the vaccine has been “heading into phase I studies”, but now the company is becoming more specific in regards to the timeframe.

Foto: PR

For some time, Lundbeck has worked intensely on developing a vaccine against Alzheimer’s disease, giving them a potential new candidate on the highly attractive dementia market, which is currently estimated at around DKK 55 billion (USD 9.84 billion) – a number that is bound to go up in coming years due in part to the demographic development on many of the major markets.

Lundbeck has been relatively quiet about the development of Vaccinil for some time, however, the recent positive developments has spurred the company to open up and get more specific about when the candidate drug could be ready for human trials.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier